FORM 4

obligations may continue. See

Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT	OF CHANGES II	N BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>SALEKI-GERHARDT AZITA</u>					2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ABBV]								5. Relationship of Reportir (Check all applicable) Director			10% Owner			
(Last) 1 N. WA	(F UKEGAN	,	(Middle))		3. Date of Earliest Transaction (Month/Day/Year) 03/05/2019								X Officer (give title Other (specify below) EVP, Operations					
(Street) NORTH CHICAC			60064 (Zip)		4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X					
		Tab	le I - N	Non-Deriv	ative	Sec	uritie	s Ad	cquire	ed, Di	isposed o	f, or E	Benefic	ially	Owne	ed			
1. Title of Security (Instr. 3)		2. Transacti Date (Month/Day		Execution Date,		<i>'</i>	Code (Instr.		Acquired (A) or (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership					
								Code	v	Amount	(A) or (D)	Price		Trans	action(s) 3 and 4)		(Instr. 4)		
Common stock, \$0.01 par value			03/05/2	019	.9			S		15,797	D	\$79.03	327(1)	93,312		D			
Common	Common stock, \$0.01 par value												2,027(2)		I	Profit Sharing Trust			
Common stock, \$0.01 par value													3,873		I	By Spouse ⁽³⁾			
		Ta	able II								oosed of, convertib				vned				
1. Title of Derivative Security (Instr. 3)	Derivative decurity lenstr. 3) Conversion or Exercise (Month/Day/Year) Price of Derivative Security Date (Month/Day/Year) (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Month/Day/Year)		4. Transa Code (8)		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5	ative rities ired osed	Expir (Mon	ration D hth/Day/	Date Amou //Year) Secur Under Derive Secur and 4)		Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number of		ice of vative urity r. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficia General Ownership (Instr. 4)			

Explanation of Responses:

- 1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$78.77 to \$79.31, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 2. Balance in AbbVie Savings program as of February 28, 2019.
- $3. \ The \ reporting \ person \ disclaims \ beneficial \ ownership \ of \ all \ securities \ held \ by \ her \ spouse.$

Remarks:

The transactions reported on this Form 4 were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

Steven L. Scrogham, attorney-

in-fact for Azita Saleki-03/05/2019

Gerhardt

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.